ES2262504T3 - Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4. - Google Patents
Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4.Info
- Publication number
- ES2262504T3 ES2262504T3 ES00904486T ES00904486T ES2262504T3 ES 2262504 T3 ES2262504 T3 ES 2262504T3 ES 00904486 T ES00904486 T ES 00904486T ES 00904486 T ES00904486 T ES 00904486T ES 2262504 T3 ES2262504 T3 ES 2262504T3
- Authority
- ES
- Spain
- Prior art keywords
- substituted
- cycloalkyl
- heterocyclic
- heteroaryl
- aryl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06173—Dipeptides with the first amino acid being heterocyclic and Glp-amino acid; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06139—Dipeptides with the first amino acid being heterocyclic
- C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Vascular Medicine (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Utilización de un compuesto de la fórmula I o II en donde R1 se selecciona del grupo formado por alquilo, alquilo sustituido, arilo, arilo sustituido, cicloalquilo, cicloalquilo sustituido, heterocíclico, heterocíclico sustituido, heteroarilo y heteroarilo sustituido; R2 se selecciona del grupo formado por alquileno con 2 a 4 átomos de carbono en la cadena alquileno, alquileno sustituido con 2 a 4 átomos de carbono en la cadena alquileno, heteroalquileno con 1 a 3 átomos de carbono y 1 a 2 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre y con 2 a 4 átomos en la cadena heteroalquileno y heteroalquileno sustituido con, en la cadena heteroalquileno, 1 a 3 átomos de carbono y 1 a 2 heteroátomos seleccionados entre nitrógeno, oxígeno y azufre y con 2 a 4 átomos en la cadena heteroalquileno; R3 se selecciona del grupo formado por hidrógeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, cicloalquenilo, cicloalquenilo sustituido, arilo, arilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico, heterocíclico sustituido o R3 se puede unir a R2 para formar un anillo fusionado de cicloalquilo, cicloalquilo sustituido, cicloalquenilo o cicloalquenilo sustituido; X se selecciona del grupo formado por hidrógeno, alquilo, alquilo sustituido, cicloalquilo, cicloalquilo sustituido, alcoxilo, alcoxilo sustituido, arilo, arilo sustituido, ariloxilo, ariloxilo sustituido, ariloxiarilo, ariloxiarilo sustituido, heteroarilo, heteroarilo sustituido, heterocíclico, heterocíclico sustituido, acilamino, carboxilo, carboxilalquilo, carboxilalquilo sustituido, carboxilcicloalquilo, carboxilcicloalquilo sustituido, carboxilarilo, carboxilarilo sustituido, carboxilheteroarilo, carboxilheteroarilo sustituido, carboxiheterocíclico, carboxiheterocíclico sustituido e hidroxilo con la condición de que en la fórmula II, X no es hidroxilo; W es oxígeno o azufre; o una sal farmacéuticamente aceptable de los mismos, en la elaboración de un medicamento para usar en el tratamiento de un paciente mamífero de una enfermedad inflamatoria mediada por VLA-4.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23866199A | 1999-01-26 | 1999-01-26 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2262504T3 true ES2262504T3 (es) | 2006-12-01 |
Family
ID=22898814
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES00904486T Expired - Lifetime ES2262504T3 (es) | 1999-01-26 | 2000-01-21 | Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4. |
Country Status (12)
| Country | Link |
|---|---|
| EP (2) | EP1612215A1 (es) |
| JP (1) | JP2002535341A (es) |
| CN (1) | CN1195773C (es) |
| AR (1) | AR022405A1 (es) |
| AT (1) | ATE323102T1 (es) |
| AU (1) | AU2623800A (es) |
| CA (1) | CA2358093A1 (es) |
| DE (1) | DE60027268T2 (es) |
| ES (1) | ES2262504T3 (es) |
| HK (1) | HK1046146B (es) |
| TW (1) | TWI224110B (es) |
| WO (1) | WO2000043413A2 (es) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6407066B1 (en) * | 1999-01-26 | 2002-06-18 | Elan Pharmaceuticals, Inc. | Pyroglutamic acid derivatives and related compounds which inhibit leukocyte adhesion mediated by VLA-4 |
| JP2002535341A (ja) * | 1999-01-26 | 2002-10-22 | エラン ファーマシューティカルズ，インコーポレイテッド | Ｖｌａ−４により媒介される白血球接着を阻害するピログルタミン酸誘導体および関連化合物 |
| JP5401218B2 (ja) * | 2009-09-03 | 2014-01-29 | 東京応化工業株式会社 | レジスト組成物、レジストパターン形成方法 |
| CN108299218A (zh) * | 2017-01-12 | 2018-07-20 | 南京红杉生物科技有限公司 | 一种4-溴-d-苯丙氨酸的合成方法 |
| CN109180552B (zh) * | 2018-09-26 | 2021-10-26 | 沈阳药科大学 | 取代的5-氧代吡咯烷类衍生物及其制备方法和应用 |
| KR20240015737A (ko) | 2018-10-30 | 2024-02-05 | 길리애드 사이언시즈, 인코포레이티드 | 알파4베타7 인테그린 억제제로서의 퀴놀린 유도체 |
| WO2020092394A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Imidazopyridine derivatives as alpha4beta7 integrin inhibitors |
| AU2019373245C1 (en) | 2018-10-30 | 2022-10-27 | Gilead Sciences, Inc. | Compounds for inhibition of alpha 4β7 integrin |
| CA3115820A1 (en) | 2018-10-30 | 2020-05-07 | Gilead Sciences, Inc. | Compounds for inhibition of .alpha.4.beta.7 integrin |
| US11578069B2 (en) | 2019-08-14 | 2023-02-14 | Gilead Sciences, Inc. | Compounds for inhibition of α4 β7 integrin |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE69530392D1 (de) * | 1994-07-11 | 2003-05-22 | Athena Neurosciences Inc | Inhibitoren der leukozytenadhäsion |
| CA2257381C (en) * | 1996-06-21 | 2007-08-21 | Takeda Chemical Industries, Ltd. | Method for producing peptides |
| CN1265670A (zh) * | 1997-07-31 | 2000-09-06 | 伊兰药品公司 | 抑制vla－4介导的白细胞粘附的二肽和相关的化合物 |
| TW591026B (en) * | 1998-06-23 | 2004-06-11 | Upjohn Co | Inhibitors of alpha4beta1 mediated cell adhesion |
| JP2002535341A (ja) * | 1999-01-26 | 2002-10-22 | エラン ファーマシューティカルズ，インコーポレイテッド | Ｖｌａ−４により媒介される白血球接着を阻害するピログルタミン酸誘導体および関連化合物 |
-
2000
- 2000-01-21 JP JP2000594829A patent/JP2002535341A/ja not_active Withdrawn
- 2000-01-21 EP EP05019666A patent/EP1612215A1/en not_active Withdrawn
- 2000-01-21 CA CA002358093A patent/CA2358093A1/en not_active Abandoned
- 2000-01-21 WO PCT/US2000/001537 patent/WO2000043413A2/en active IP Right Grant
- 2000-01-21 CN CNB00803107XA patent/CN1195773C/zh not_active Expired - Fee Related
- 2000-01-21 AU AU26238/00A patent/AU2623800A/en not_active Abandoned
- 2000-01-21 DE DE60027268T patent/DE60027268T2/de not_active Expired - Fee Related
- 2000-01-21 EP EP00904486A patent/EP1144435B1/en not_active Expired - Lifetime
- 2000-01-21 ES ES00904486T patent/ES2262504T3/es not_active Expired - Lifetime
- 2000-01-21 AT AT00904486T patent/ATE323102T1/de not_active IP Right Cessation
- 2000-01-24 AR ARP000100291A patent/AR022405A1/es unknown
- 2000-01-25 TW TW089101188A patent/TWI224110B/zh not_active IP Right Cessation
-
2002
- 2002-09-20 HK HK02106863.9A patent/HK1046146B/zh not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| CN1195773C (zh) | 2005-04-06 |
| TWI224110B (en) | 2004-11-21 |
| EP1612215A1 (en) | 2006-01-04 |
| EP1144435B1 (en) | 2006-04-12 |
| EP1144435A2 (en) | 2001-10-17 |
| ATE323102T1 (de) | 2006-04-15 |
| WO2000043413A2 (en) | 2000-07-27 |
| AR022405A1 (es) | 2002-09-04 |
| DE60027268D1 (de) | 2006-05-24 |
| HK1046146B (zh) | 2005-07-29 |
| AU2623800A (en) | 2000-08-07 |
| HK1046146A1 (en) | 2002-12-27 |
| DE60027268T2 (de) | 2007-03-15 |
| JP2002535341A (ja) | 2002-10-22 |
| CN1344274A (zh) | 2002-04-10 |
| CA2358093A1 (en) | 2000-07-27 |
| WO2000043413A3 (en) | 2000-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05003193A (es) | Compuesto de adenina novedoso y uso del mismo. | |
| LU91196I2 (fr) | Picoxystrobin et ses dérivlés pharmaceutiquement acceptables(ACANTO). | |
| KR890701557A (ko) | 리폭시게나제 억제화합물을 함유하는 푸란 및 피롤 | |
| HUP0201646A2 (hu) | Új alfa-aminosav vegyületek, eljárás ezek előállítására, és ezeket tartalmazó gyógyászati készítmények | |
| AR029216A1 (es) | Compuestos inhibidores no peptidicos de la union celular dependiente de vla-4 utiles en el tratamiento de enfermedades inflamatorias, autoinmunes y respiratorias; composicion farmaceutica y procedimiento de tratamiento | |
| BRPI0014526B8 (pt) | compostos cíclicos de seis elementos contendo nitrogênio aromático, composição farmacêutica e uso do mesmo | |
| EA200300792A1 (ru) | Хиназолины в качестве ингибиторов ммр-13 | |
| ES2112332T3 (es) | Derivados de substitucion de oxigeno de productos de adicion de nucleofilo-oxido nitrico utilizados como promedicamentos donadores de oxido nitrico. | |
| EA200100755A1 (ru) | 4-оксо-1,4-дигидро-3-хинолинкарбоксамиды как антивирусные агенты | |
| EA200000731A1 (ru) | Альфа-аминоамидные производные, полезные в качестве анальгетических агентов | |
| FI942635A (fi) | Piperatsiinijohdannaiset 5HT1A-antagonisteina | |
| EA200300333A1 (ru) | Новые тиадиазолы и оксадиазолы и их применение в качестве ингибиторов фосфодиэстеразы-7 | |
| ES2262504T3 (es) | Derivados del acido piroglutamico y compuestos afines que inhiben la adhesion de leucocitos mediada por la vla-4. | |
| AR039190A1 (es) | Derivados de benzofurano, composicion farmaceutica y medicamento que comprende el compuesto | |
| HUT38918A (en) | Process for production of 2-amino-axazilons and medical preparatives containing thereof | |
| FI940419A0 (fi) | Uusi bisheterosyklinen johdos tai sen suola | |
| DK112688A (da) | Heterocykliske forbindelser | |
| DE69229637D1 (de) | Oxazolidone Derivative als Monoamine-Oxidaseinhibitoren | |
| SE8804688L (sv) | Substituerade styrenderivat | |
| FI853233L (fi) | 1,6-naftyridinderivat, foerfarande foer deras framstaellning och dessa innehaollande farmaceutiska produkter. | |
| AR027454A1 (es) | Derivados de beta-alanina, utiles como antagonistas de receptores, las composiciones farmaceuticas que las contienen y el uso de los mismos para lapreparacion de medicamentos | |
| KR900001701A (ko) | 이미다조피라졸 유도체의 진통제 및 항염제로서의 용도 | |
| DE59009388D1 (de) | Pharmazeutisch wirksame Pteridinderivate. | |
| ATE257826T1 (de) | Benzimidazolderivate und sie enthaltende medikamente | |
| EP1433479A4 (en) | AGENTS STIMULATING THE APPETITE AND REMEDIES AGAINST ANOREXIA |